• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21720 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     NIHR Health Technology Assessment programme Anaesthetic analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening and prevention programmes for children and adolescents from 6 to 14 years. Results from selected countries and recommendations from evidence-based guidelines
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening for Diabetes mellitus: guideline recommendations
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep anterior lamellar keratoplasty in keratoconus]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Negative pressure wound therapy for wounds healing by secondary intention]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Shoulder prosthesis in complex proximal humeral fractures]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) FoundationOne®CDx: genetic profiling of solid tumours
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac monitors in syncope of unknown etiology]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Rapid on-site evaluations of cytological punctures]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     NIHR Health Technology Assessment programme Manualised cognitive behavioural therapy in treating depression in advanced cancer: the CanTalk RCT
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Per-oral endoscopic myotomy (POEM) in achalasia]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography: usefulness in glaucoma, diabetic retinopathy and age-related macular degeneration]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2019     NIHR Health Technology Assessment programme Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer (ID56)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Video head impulse test in vertigo]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening programs for children and adolescents from 6 to 18 years. Results on selected countries, Austrian screening programmes and recommendations from evidence-based guidelines
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Palivizumab for the prevention of respiratory syncytial virus lower respiratory tract infections]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Cerenkov lluminescence imaging system for intraoperative assessment of surgical margins in breast, prostate, and gastrointestinal cancer]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Sacral nerve stimulation/neuromodulation in bladder and/or bowel incontinence]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019     Agency for Healthcare Research and Quality (AHRQ) Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance]
2019     NIHR Health Technology Assessment programme An evaluation of the feasibility of conducting a randomised clinical trial to evaluate the clinical and cost-effectiveness of a more permissive temperature threshold for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility study
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge, state of practice: Use of direct oral anticoagulants and warfarin in the context of atrial fibrillation and venous thromboembolism]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Economic, organization and safety impact of drug robotic dispensing in Spanish hospitals]
2019     NIHR Health Technology Assessment programme Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) POCT/ Point of Care Tests: D-Dimer and Troponin
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: anticoagulant therapy]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) -Addendum to Commission A18-53]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Powder bed fusion manufacturing of titanium for customized bone replacements in craneomaxillofacial reconstruction]
2019     Medical Services Advisory Committee (MSAC) Digital breast tomosynthesis
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Minimum volume standards for quality assurance in day surgery: Fundamentals and Systematic Review
2019     Penn Medicine Center for Evidence-based Practice (CEP) Pulmonary Artery Catheters Catheter Dwell Time and Routine Replacement
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tildrakizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2019     NIHR Health Technology Assessment programme Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT
2019     Penn Medicine Center for Evidence-based Practice (CEP) Dual Antiplatelet Therapy Following Revascularization for Peripheral Artery Disease
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Lenvatinib for iodine-refractory differentiated thyroid cancer]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     NIHR Health Technology Assessment programme Electronically delivered interventions to reduce antibiotic prescribing for respiratory infections in primary care: cluster RCT using electronic health records and cohort study
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Irreversible electroporation for the treatment of liver and pancreatic cancer]
2019     Penn Medicine Center for Evidence-based Practice (CEP) Dosing of Botulinum Toxin for Neurologic Indications
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) Diagnostic accuracy and clinical utility of PET/CT amyloid in mild cognitive impairment
2019     Andalusian Health Technology Assessment Area (AETSA) Genetic diseases in Spain. Map of genetic test available in the National Health System. Upgrade.
2019     Penn Medicine Center for Evidence-based Practice (CEP) Management of Tunneled Dialysis Catheters in Patients with Bloodstream Infection
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (cystic fibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Agency for Healthcare Research and Quality (AHRQ) Management of infertility
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: antidiabetics]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: autonomy in intellectually disabled young people aged 6 to 21 years]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: axicabtagene ciloleucel for the treatment of relapsed or refractory large B-cell lymphoma]
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A18-66]
2019     NIHR Health Technology Assessment programme Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (melanoma) - Addendum to Commission A18-59]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (melanoma) - Addendum to Commission A18-60]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - Addendum to Commission A18-63]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Addendum to Commission A18-61]
2019     NIHR Health Technology Assessment programme Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Cutaquig, preparation of human immunoglobulins, notice of inclusion on the Liste des produits du système du sang du Québec]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib (melanoma) - Addendum to Commission A18-62]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of newborn blood spot screening for biotinidase deficiency (BIOT)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     NIHR Health Technology Assessment programme Exercise or manual physiotherapy compared with a single session of physiotherapy for osteoporotic vertebral fracture: three-arm PROVE RCT
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Addendum to Commission A18-69]
2019     Center for Drug Evaluation (CDE) Assessment of the benefits of community day-care facilities for the physically and mentally handicapped
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Localized and disseminated stages of Lyme disease: from diagnosis to treatment, report in support of the diagnosis and treatment decision support tools]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in June 2019: acute exacerbations of chronic obstructive pulmonary disease (AECOPD)]
2019     Agency for Care Effectiveness (ACE) Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in June 2019: urethral discharge]
2019     Agency for Care Effectiveness (ACE) Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     NIHR Health Technology Assessment programme Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT